【Abstract】Objective To explore the dynamic expression of TNF-α and VEGF in the development of esophageal varices in rats with portal hypertension. Methods Sixty male SD rats were randomly divided into the experimental group and the control group. In the experimental group, a two-stage ligation of portal vein plus ligation of the left adrenal vein was performed.After establishment of the model, the expression of TNF-α、VEGF and PCNA in the lower esophagus was detected with immunohistochemical SP technique on 7 d、14 d、21 d and comparision of these data with control group was performed respectively. In the control group, a sham-operation was performed, was also divided.Results The portal venous pressure in the experimental group was significantly higher than that of the control, so did the vessel number and the total vascular area of the submucosal veins in the lower esophagus. Compared with the control subgroups, the expression of TNF-α and VEGF on the 21 d subgroup was ber, while PCNA was ber on the 14 d and 21 d. Conclusion In the development of esophageal varices of portal hypertension, VEGF possibly plays a role in the varices developemt, and TNF-α may be responsible for the damage of esophageal mucosa.
Objective To evaluate the efficacy and safety of endoscopic variceal ligation (EVL) versus endoscopic variceal sclerotherapy (EVS) for acute esophageal variceal bleeding in patients with liver cirrhosis.Methods We searched CBMdisc (1979 to 2006), CNKI (1994 to 2006) and VIP for randomized controlled trials (RCTs) and quasi-RCTs comparing EVL and EVS for acute esophageal variceal bleeding patients with liver cirrhosis. The methodogical quality of included trials was critically assessed and the data were extracted by two reviewers, working independently. The Cochrane Collaboration’s RevMan 4.2.7 software was used for meta-analysis. Results Nine RCTs involving a total of 1371 patients were included: 688 in EVL group and 683 in EVS. The meta-analyses showed a significant reduction for mortality [RR 0.60, 95%CI (0.36, 0.98)], and non-significant reductions in complications, rebleeding and emergency hemostasis in the EVL group compared to the EVS group. EVS was non-significantly better than EVL for the rate of eradication varices and recurrent varices. Conclusions For acute esophageal variceal bleeding in patients with liver cirrhosis, EVL has better effect and fewer complications than EVS. However, because the quality of included RCTs was poor, the strength of our conclusions was limited. Further high-quality RCTs are required.
目的 比较CT门静脉血管成像（CTP）与内镜诊断肝硬化胃食管静脉曲张的效果，探讨CTP对肝硬化门静脉高压侧支循环血管的显示及其在随访中的价值。 方法 对2010年1月－2011年12月收治的43例肝硬化患者行多排螺旋CT增强扫描门静脉血管成像，观察胃食管静脉曲张程度，及有无其他侧支开放，并在4周内行内镜检查，了解胃食管静脉曲张的程度。 结果 43例患者中有33例经胃镜确诊食管静脉曲张，其中CTP诊断与胃镜相符29例；胃镜诊断胃底静脉曲张14例，其中有12例CTP诊断与之相符；CTP诊断胃食管静脉曲张与内镜有较好的相关性和一致性，但在判断食管静脉曲张部位上与胃镜一致性较差。 结论 对肝硬化患者可采用CTP进行随访，以评估胃食管静脉曲张出血风险，可减少不必要的内镜随访。
目的 观察内镜下食管静脉曲张套扎术联合药物治疗肝硬化食管静脉曲张出血的临床疗效。 方法 回顾性分析2007年2月－2010年8月56例确诊为肝硬化食管静脉曲张出血患者，随机分为联合治疗组和对照组，各28例。对照组行胃镜下套扎术联合生长抑素、泮托拉唑；联合治疗组行内镜下套扎术联合生长抑素、泮托拉唑、普萘洛尔等药物治疗。观察所有食管静脉曲张出血患者1、3、6、12、18个月后随访，两组近期再出血率、食管曲张静脉消失率及复发率、不良反应及并发症的情况。 结果 联合治疗组曲张静脉消失率、不良反应及并发症与对照组比较，差异无统计学意义（P＞0.05）；联合治疗组近期再出血及食管静脉曲张复发等发生率明显低于对照组，差异有统计学意义（P＜0.05）。 结论 食管静脉曲张套扎术联合药物是治疗食管静脉曲张出血一种安全有效的方法，疗效确切，提高了患者生存率。
【摘要】 目的 探讨肝硬化食管静脉曲张程度与门脾静脉内径、肝功能Child-Pugh分级间的关系。 方法 对2007年1月-2010年1月间56例肝硬化患者行增强CT，测量门静脉主干及脾门部脾静脉直径，采用Child-Pugh分级标准进行肝功能分级，并行胃镜了解食管静脉曲张的程度。 结果 食管静脉曲张程度与门、脾静脉内径呈正相关，而Child-Pugh分级与门脾静脉内径、食管静脉曲张程度无相关性。 结论 根据门、脾静脉内径可预测肝硬化上消化道出血的可能性；在Child-Pugh分级基础上对患者上消化道出血的风险进行评估显得尤为重要。【Abstract】 Objective To discuss the relationship among the esophageal varices, the diameter of portal vein and spleen vein, and Child-Pugh score in patients with liver cirrhosis. Methods The study included 56 patients who had liver cirrhosis between January 2007 and January 2010. We measured their portal vein and spleen vein diameter with CT; used Child-Pugh score to grade their hepatic function; and detected the degree of the esophageal varices by endoscopy. Results There was a positive correlation between the degree of esophageal varices and diameter of portal vein and spleen vein, while no correlation showed between portal vein and spleen vein diameter, degree of esophageal varices, and Child-Pugh score. Conclusion The upper gastrointestinal bleeding in patients with liver cirrhosis can be predicted by the diameter of portal vein and spleen vein, assessment of upper gastrointestinal bleeding based on Child-Pugh score should also be taken into account.
目的:观察比较胃镜下硬化剂注射联合药物治疗和单纯硬化剂注射治疗、药物治疗食管静脉曲张出血的疗效。方法:95例肝硬化并食管静脉曲张出血患者,分成三组。32例患者给予硬化剂注射联合药物治疗,31例患者给予硬化剂治疗,32例患者给予药物治疗。观察三组患者急诊止血率,近期出血率、远期再出血率、曲张静脉消失率、曲张静脉复发率。 结果: 联合组、硬化剂组、药物组急诊止血率分别为93.8%.90.3%、68.8%;联合组、硬化剂组、药物组近期出血率分别为6.3%、9.7%、46.9%;联合组、硬化剂组、药物组曲张静脉消失率分别为90.6%、83.9%、1.9%;联合组、硬化组与药物组急诊止血率、近期出血率、曲张静脉消失率有显著差异。联合组、硬化剂组、药物组远期出血率分别为9.4%、59.4%、31.3%; 联合组、硬化剂组、药物组曲张静脉复发率分别为18.8%、45.2%、87.5%;联合组与硬化组、药物组远期出血率、曲张静脉复发率有显著差异。结论:胃镜下硬化剂注射联合药物治疗食管静脉曲张出血可显著提高疗效。
目的 探讨肝硬变门脉高压上消化道出血的原因及临床特点。方法 对121例肝硬变门脉高压伴上消化道出血患者急诊胃镜检查(48小时内)结果进行了分析。结果 本组病例中肝硬变非食管静脉曲张破裂出血占肝硬变上消化道出血病例的33%(40/121)，其中门脉高压性胃病24例，消化性溃疡12例，胃癌及病灶不详4例。结论 肝硬变非食管静脉曲张破裂所致出血中以肝硬变门脉高压性胃病出血最为多见，其出血方式各异，出血量大小不等，有诱因者较多，并发症亦较多。临床上应注意与食管静脉曲张破裂出血鉴别。
ObjectiveTo explore an individualized treatment program to prevent the initial bleeding of a patient with cirrhosis and esophageal varices by the methods of evidence-based medicine. MethodsOne patient with cirrhosis and esophageal varices was admitted into our hospital on November 2, 2013. After evaluating the patient's condition adequately, we proposed the problem according to the PICOS principles. Then, we assessed the clinical evidence from the Cochrane Library (1990-2012), Medline (1950-2012), Embase (1991-2012), VIP (1989-2013), and CBM (1990-2013). The individualized treatment plan was made through doctors' experiences and analysis of those high-quality evidences from the databases. ResultsEight studies (randomized controlled trials and 5 meta-analysis) were included. We evaluated a series of associated problems:whether we should take measurement to prevent initial bleeding of esophageal varices; which one (β-blockers or ligation of esophageal varices) was the best method to prevent the initial bleeding based on efficacy, complication and cost-effectiveness. Then, according to the evidences and the patient's view, we gave non-selectiveβ-blocker as the primary prevention. After one-year followed-up, the initial bleeding of the patient did not occur. ConclusionMaking the prevention plan for a patient with cirrhosis and esophageal varices can not only find out the individualized program, but also push the patient to make decision for their own health.